Autolus Therapeutics plc (AUTL) Net Income (Loss) Attributable to Parent USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Autolus Therapeutics plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2017 to 2024.
  • Autolus Therapeutics plc Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$52.7 M, a 32.4% decline year-over-year.
  • Autolus Therapeutics plc Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$221 M, a 46% decline year-over-year.
  • Autolus Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2023 was -$208 M, a 40% decline from 2022.
  • Autolus Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2022 was -$149 M, a 4.75% decline from 2021.
  • Autolus Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2021 was -$142 M, a 0% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$221 M -$52.7 M -$12.9 M -32.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-17
Q4 2023 -$208 M -$77.2 M -$50.2 M -186% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$158 M -$45.8 M -$3.08 M -7.21% Jul 1, 2023 Sep 30, 2023 10-K 2024-03-21
Q2 2023 -$155 M -$45.6 M -$3.49 M -8.31% Apr 1, 2023 Jun 30, 2023 10-K 2024-03-21
Q1 2023 -$152 M -$39.8 M -$2.75 M -7.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-17
Q4 2022 -$149 M -$27 M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$42.8 M Jul 1, 2022 Sep 30, 2022 10-K 2024-03-21
Q2 2022 -$42.1 M Apr 1, 2022 Jun 30, 2022 10-K 2024-03-21
Q1 2022 -$37.1 M -$3.8 M -11.4% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-21
Q1 2021 -$145 M -$33.3 M -$3.39 M -11.4% Jan 1, 2021 Mar 31, 2021 6-K 2021-05-06
Q4 2020 -$142 M -$42.9 M -$1.92 M -4.68% Oct 1, 2020 Dec 31, 2020 20-F 2023-03-07
Q3 2020 -$140 M -$37.3 M -$10.1 M -36.9% Jul 1, 2020 Sep 30, 2020 6-K 2020-11-05
Q2 2020 -$130 M -$32 M -$3.57 M -12.5% Apr 1, 2020 Jun 30, 2020 6-K 2020-08-06
Q1 2020 -$127 M -$29.9 M -$2.69 M -9.91% Jan 1, 2020 Mar 31, 2020 6-K 2021-05-06
Q4 2019 -$124 M -$40.9 M -$20.3 M -98.3% Oct 1, 2019 Dec 31, 2019 20-F 2022-03-10
Q3 2019 -$104 M -$27.2 M -$14.4 M -112% Jul 1, 2019 Sep 30, 2019 6-K 2020-11-05
Q2 2019 -$89.2 M -$28.5 M -$20.8 M -272% Apr 1, 2019 Jun 30, 2019 6-K 2020-08-06
Q1 2019 -$68.3 M -$27.2 M -$10.5 M -62.6% Jan 1, 2019 Mar 31, 2019 6-K 2020-08-06
Q4 2018 -$57.9 M -$20.6 M -$13.1 M -174% Oct 1, 2018 Dec 31, 2018 20-F 2021-03-04
Q3 2018 -$44.8 M -$12.9 M Jul 1, 2018 Sep 30, 2018 6-K 2019-11-07
Q2 2018 -$7.65 M Apr 1, 2018 Jun 30, 2018 6-K 2019-08-08
Q1 2018 -$16.7 M Jan 1, 2018 Mar 31, 2018 6-K 2019-08-08
Q4 2017 -$7.52 M Oct 1, 2017 Dec 31, 2017 20-F 2019-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.